Superworth

Metagenomi Therapeutics revenue MGX

Sales by quarter and over the last twelve months, from 2023.

Last 12 months, to Mar 31, 2026
$22.3M
Latest quarter, Q1 FY26
$1.2M
−70% on a year earlier
Fiscal year 2025
$25.2M
−52% on the year before

Metagenomi Therapeutics' revenue was $22.3M over the twelve months to Mar 31, 2026, down 51% on a year earlier.

In its latest quarter, Q1 FY26, it was $1.2M, down 70% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$25.2M−52%
FY2024$52.3M+17%
FY2023$44.8Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q1 FY26$1.2M−70%$22.3M
Q4 FY25$3.9M−59%$25.2M
Q3 FY25$8.7M−25%$30.9M
Q2 FY25$8.5M−57%$33.8M
Q1 FY25$4.1M−63%$45.3M
Q4 FY24$9.6M−22%$52.3M
Q3 FY24$11.5M−7%$55.1M
Q2 FY24$20M+76%$55.9M
Q1 FY24$11.2M+29%$47.3M
Q4 FY23$12.4Mn/a$44.8M
Q3 FY23$12.4Mn/an/a
Q2 FY23$11.3Mn/an/a

Against its peers

Companies in Healthcare nearest Metagenomi Therapeutics' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
MGXMetagenomi Therapeuticsn/m
NEPHNephros$20.7M+24% a year
ATNMActinium Pharmaceuticalsn/m
APTAlpha Pro Tech$61.9M+6% a year
SPROSpero Therapeutics$47M−3% a year
LFVNLifevantage$182.6M−20% a year
ICCCImmucell$30.7M+8% a year
KEQUKewaunee Scientific$277.2M+5% a year
PDEXPro DEX$77.5M+16% a year
PLXProtalix BioTherapeutics$80.6M+30% a year
NATRNatures Sunshine Products$492M+7% a year
Peer median$77.5M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Metagenomi Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.